This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. AIM ImmunoTech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.004. AIM ImmunoTech's 10-Year median PS Ratio is 162.5. Therefore, the Median PS Value for today is $0.65.
As of today (2024-04-28), AIM ImmunoTech's share price is $0.4282. AIM ImmunoTech's Median PS Value is $0.65. Therefore, AIM ImmunoTech's Price to Median PS Value for today is 0.66.
The historical rank and industry rank for AIM ImmunoTech's Median PS Value or its related term are showing as below:
AIM'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06 Med: 0.67 Max: 1.61
Current: 0.66
During the past 13 years, the highest Price to Median PS Value of AIM ImmunoTech was 1.61. The lowest was 0.06. And the median was 0.67.
AIM's Price-to-Median-PS-Value is ranked worse than 50.58% of 259
companies
in the Biotechnology industry
Industry Median: 0.65
vs AIM: 0.66
AIM ImmunoTech Median PS Value Historical Data
The historical data trend for AIM ImmunoTech's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AIM ImmunoTech's Median PS Value
For the Biotechnology subindustry, AIM ImmunoTech's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Price-to-Median-PS-Value falls into.
AIM ImmunoTech Median PS Value Calculation
AIM ImmunoTech's Median PS Value for today is calculated as
10-Year Median PS Ratio is 162.5.
AIM ImmunoTech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AMEX:AIM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
AIM ImmunoTech's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.4282
/
0.65
=
0.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech Median PS Value Related Terms
Thank you for viewing the detailed overview of AIM ImmunoTech's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
AIM ImmunoTech (AIM ImmunoTech) Business Description
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AIM has been successfully added to your 